Clinical Trial Update: A Trial of Durvalumab (MEDI4736) Plus Monalizumab in Non-Muscle-Invasive Bladder Cancer [Phase 2]

View source ↗

Summary

This clinical trial update reports a Phase 2 study of durvalumab plus monalizumab for non-muscle invasive bladder cancer, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-muscle Invasive Bladder Cancer

Drugs mentioned

• Durvalumab (durvalumab)
• Monalizumab (monalizumab)

Snippet

Sponsor: John Sfakianos | Conditions: Non-muscle Invasive Bladder Cancer, Non-Muscle Invasive Bladder Urothelial Carcinoma | Phase 2 | Status: RECRUITING